Molecular docking studies of bisazo derivatives of 4-Acetyl resorcinol against lung cancer protein EGFR

Abstract

Lung cancer is one of the malignant diseases mostly caused by tobacco users. EGFR, proto oncogene plays an important role in many biological processes apoptosis, transcriptional regulation, cell differentiation, cell spreading and mobility. The mutation occurs in EGFR, the normal function of EGFR is over expressed and leads to develop lung cancer. In this present study, we have developed lung cancer drug from bisazo derivatives through molecular docking studies against EGFR using Glide. From the docking results the compound I, IV and V have a better life score when compared to other compounds. The ADME properties were carried out for five bis azo molecules. These compounds are under acceptable range with predicted ADME properties. From the In-silico docking studies, we conclude the compounds I, IV and V are good drug for  lung cancer and inhibit over expression of EGFR in human.